SecBot SecBot
Biotech Drug Report Generated Nov 7, 2026

Vanguard B Oral

ZTS·Zoetis Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved/Marketed
Time to market
Already on the market. The product has been commercially available in the U.S. since at least 2016 and is also sold in Brazil, New Zealand, and other international markets.
Why 3/10
Vanguard B Oral is already approved and commercially marketed (USDA-licensed, on the market since at least 2016). There is no pending PDUFA, pivotal readout, or other hard binary catalyst scheduled for this product in the next 12 months. The recent Brazil label expansion (announced November 5, 2026) is a routine commercial update, not a stock-moving binary event. Per the impact score rubric, an approved, marketed drug with no pending regulatory decision scores 3-5, and as a small part of a large diversified portfolio, the score is at the low end.
Actionable Insight NEUTRAL

Vanguard B Oral is a mature, already-commercialized product with no pending regulatory decision or pivotal readout. The next incremental catalyst would be additional geographic label expansions (like the recent Brazil claim), but these are routine commercial updates, not stock-moving binary events. For Zoetis investors, the product is a small contributor within a $9.5B+ revenue portfolio; watch Zoetis's quarterly companion-animal vaccine franchise trends instead.

Price Chart

Loading chart...

Executive Summary

Vanguard B Oral is a USDA-licensed, commercially marketed oral vaccine from Zoetis Inc. (NYSE: ZTS) that protects dogs against Bordetella bronchiseptica, a primary cause of kennel cough. It has been on the market since at least 2016 and is the only oral Bordetella vaccine with a USDA-verified 1-year duration of immunity. In November 2026, Zoetis announced an additional label claim for the product in Brazil. However, as a mature product within Zoetis's diversified $9.5B+ revenue portfolio, Vanguard B Oral is not a material standalone driver of Zoetis's stock price, and there are no upcoming binary catalysts (PDUFA dates or pivotal readouts) for this product.

How It Works

Vanguard B Oral is a live, weakened (avirulent) culture of Bordetella bronchiseptica bacteria given by mouth to dogs. It works by stimulating the dog's immune system in the mouth and throat to produce protective antibodies against kennel cough, without causing the disease itself. The vaccine is administered as a 1 mL dose into the cheek pouch, using either a syringe or a syringe-free applicator.

Trial Status

Vanguard B Oral is a USDA-licensed veterinary biological product already in commercial use. A 2026 peer-reviewed study in the American Journal of Veterinary Research confirmed a 7-day onset of immunity in dogs. The product has demonstrated a USDA-verified 1-year duration of immunity.

The Two-Sided Case

▲ Bull Case4
Vanguard B Oral is the only oral Bordetella vaccine with a USDA-verified 1-year duration of immunity, a differentiating claim versus some competing products.
The product recently received an additional label claim in Brazil (announced November 5, 2026), expanding its addressable market in a major pet-owning region.
A peer-reviewed study (American Journal of Veterinary Research, 2026) demonstrated a rapid 7-day onset of protective immunity, supporting the product's clinical profile.
Oral administration avoids the 'messy sneeze-backs' of intranasal vaccines and the needle-stick concerns of injectables, offering a convenience advantage in veterinary clinics.
▼ Bear Case3
Vanguard B Oral faces competition from multiple alternative Bordetella vaccine formats: Zoetis's own newer Vanguard Recombishield injectable (launched November 2025), Merck's Nobivac Intra-Trac Oral Bb, and Elanco's TruCan B Oral, all targeting the same kennel-cough market.
As a mature product in a large portfolio, Vanguard B Oral is not material enough to Zoetis's $9.5B+ revenue base to drive the stock on its own, so even positive label expansions have limited share-price impact.
The product is a live-attenuated vaccine requiring cold-chain shipping, which adds logistical complexity and cost versus some competitors.

Upcoming Catalysts

  • Additional international label expansions or regulatory approvals in new geographies (routine, not binary)
  • Zoetis quarterly earnings reports (next: Q4 2026 / full-year 2026, expected early February 2027) where Vanguard franchise performance may be mentioned

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Zoetis Inc. 8-K ZTS ·Originating report

Sources · 9

Hover a chip for the title
1 zoetisus.com2 news.zoetis.com3 zoetisus.com4 drugs.com5 zoetis.com6 zoetispetcare.com7 aphis.usda.gov8 s203.q4cdn.com9 avmajournals.avma.org